U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07023835) titled 'Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis' on June 02.

Brief Summary: Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

Study Start Date: Sept., 2025

Study Type: INTERVENTIONAL

Condition: Amyotrophic Lateral Sclerosis (ALS)

Intervention: DRUG: 50 mg Usnoflast

50 mg Usnoflast (50 mg Usnoflast capsules and matching placebo of 25 mg capsule)

DRUG: 75 mg Usnoflast

75 mg Usnoflast (25 mg + 50 mg Usnoflast capsules)

DRUG: Placebo

Matching placebo of 25 mg and 50 mg

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Zydus Therapeutics ...